AIDS Vaccine 2009 - Archived Presentations

Permission from the presenting author was required to archive their presentation slides.

Monday, 19 October Tuesday, 20 October Wednesday, 21 October Thursday, 22 October

 

Monday, 19 October 2009

08:00 - 16:00 Satellite Sessions

17:00 - 18:30 Welcome and Opening Remarks
Jean-François Delfraissy, ANRS, France
Presentation
Alan Bernstein, Global HIV Vaccine Enterprise, USA
Michel Kazatchkine, The Global Fund to Fight AIDS, Tuberculosis and Maleria, Switzerland
Michel Sidibé, UNAIDS, Switzerland

17:40 - 18:05 The state of HIV prevention: How well are we doing in preventing HIV worldwide, and how can we do better?
Peter Piot, Global Health Institute, Imperial College, UK
Presentation

18:05 - 18:30 Partner, participants and problem-solvers: Expanding from "Informed Consent" to "Informed Communities" in the Search for the AIDS Vaccine
Mitchell Warren, AVAC, USA
Presentation

 

Tuesday, 20 October 2009

08:30 - 10:00 Special Session: Recent Lessons From Clinical Trials

08:30 - 09:00 AIDS Vaccine Clinical Evaluation: Where Are We and Where Can We Go?
Gary Nabel, Vaccine Research Center, NIH, USA

09:00 - 09:20 Clinical Outcomes from the STEP Study
Susan Buchbinder, HIV Research Section, San Francisco Department of Public Health, USA

09:20 - 09:40 Recent Immunologic Findings from the Step and Related HIV Vaccine Clinical Trials
Nicole Frahm, Fred Hutchinson Cancer Research Center, USA
Presentation

09:40 - 10:00 Interim Efficacy Analysis of HVTN 503/Phambili: A phase IIB test of concept trial of the MRKAd5 HIV-1 gag/pol/nef vaccine conducted in HIV-1 uninfected adults in South Africa
Glenda Gray, Perinatal HIV Research Unit, University of Witwatersrand, South Africa
Presentation

10:00 - 10:50 New Session: Spotlight on RV144, the phase III Thai trial

10:00 - 10:15 Phase III Trial of HIV Prime-Boost Vaccine Combination in Thailand: Result of Final Analysis
Supachai Rerks-Ngarm, Ministry of Health, Thailand
Presentation

10:15 - 10:30 Primary and Subgroup Analyses of the Thai Phase III HIV Vaccine Trial
Nelson L. Michael, U.S. Military HIV Research Program (MHRP), USA
Presentation

10:30 - 10:40 Question and Answer Session

10:40 - 10:50 Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boost vaccination in RV144, the Thai phase III HIV vaccine trial
Mark de Souza, U.S. Military HIV Research Program/AFRIMS, Thailand
Presentation

10:50 - 11:15 Coffee Break

11:15 - 12:45 Plenary Session 1: Initiation of the Immune Response

11:15 - 11:45 Innate Control of Adaptive Immunity to Vaccines and Pathogens
Bali Pulendran, Emory Vaccine Center, Emory University, USA

11:45 - 12:15 Harnessing Human Dendritic Cell Subsets for HIV Vaccines
Jacques Banchereau, Baylor Institute for Immunology Research, USA

12:15 - 12:45 T cell control and viral escape
Phil Goulder, University of Oxford, UK

12:45 - 14:00 Lunch + Poster Session 01

14:00 - 16:00 Symposium 1: Mechanisms of Protection against Transmission and Disease Protection

14:00 - 14:25 Epigenetic control of retroelements
Didier Trono, École Polytechnique Fédérale de Lausanne, Switzerland

14:25 - 14:50 Crosstalk between RNAi and HIV
Monsef Benkirane, Institut de Génétique Humaine, France

14:50 - 15:15 Regulation of Harmful Immune Activation during Non Pathogenic SIVagm Infection in African Green Monkeys
Michaela Müller Trutwin, Institut Pasteur, France
Presentation

15:15 - 15:30 Phenotypic Analyses of CD8+ T cells that Mediate Virus Inhibition from HIV-1 Vaccinees and HIV-1+ Virus Controllers
Stephanie Freel, Duke University Medical School, USA

15:30 - 15:45 HLA-A*7401 is Associated with Protection from HIV-1 Acquisition and Disease Progression in Mbeya, Tanzania
Rebecca Koehler, US Military HIV Research Program / Henry M Jackson Foundation, USA
Presentation

15:45 - 16:00 HIV Specific T Cell Responses and Response Patterns Associated with Viral Control Indent of Classical Non-Progessor HLA class I Alleles
Christian Brander, Irsicaixa AIDS Research Institute, Spain
14:00 - 16:00 Symposium 2: Generation of Antibody Responses and Diversity
14:00 - 14:25 Regulation of Broadly Neutralizing Antibody Responses: The Initial B Cell Repertoire To HIV-1 Envelope
Barton Haynes, Duke University Medical Center, USA

14:25 - 14:50 Factors Associated with the Development of HIV Neutralization Breadth
Lynn Morris, National Institute for Communicable Diseases, South Africa

14:50 - 15:15 Eliciting Broad Anti-HIV Neutralizing Antibodies by Vaccination: Lessons Learned from Natural Infection
Leonidas Stamatatos, Seattle Biomedical Research Institute, USA
Presentation

15:15 - 15:30 A Large-Scale Analysis of Immunoglobulin Sequences Derived From Plasmablasts/Plasma Cells in Acute HIV-1 Infection Subjects
Supriya Munshaw, Duke University, USA

15:30 - 15:45 Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface
Mikyung Kim, Dana-Farber Cancer Institute, USA

15:45 - 16:00 Potent and Broad Neutralizing Antibodies from HIV-1 non-Clade B Infected Donor Reveal a New HIV-1 Vaccine Target
Sanjay Phogat, IAVI, USA
16:00 - 17:00 Coffee Break + Poster Viewing

17:00 - 18:30 Oral Abstract Session 1: Early Events in Transmission and Infection

17:00 - 17:15 Early events of human immunodeficiency virus type 1 (HIV-1) ex vivo penetration in the foreskin mimicking HIV-1 sexual transmission
Yonatan Ganor, Cochin Institute, France

17:15 - 17:30 Defining the Mechanisms of HIV Entry and Interactions with the Female Genital Tract
Ann Carias, Northwestern University, USA
Presentation

17:30 - 17:45 Clusterin, a natural ligand of DC-SIGN present in human semen inhibits HIV capture and transmission by dendritic cells
Juan Sabatte, National Reference Center for AIDS, Argentina

17:45 - 18:00 Striking elevations in systemic and mucosal cytokine and chemokine levels in acute HIV-1 infection.
Andrea Stacey, Jenner Institute, University of Oxford, UK
Presentation

18:00 - 18:15 TLR-mediated pDC responses to HIV-1 ligands
J. Judy Chang, Ragon Institute of MGH, MIT and Harvard, USA
Presentation

18:15 - 18:30 HIV-1 Plasma RNA Risk of HIV-1 Transmission
Jairam Lingappa, University of Washington, USA
Presentation

17:00 - 18:30 Oral Abstract Session 2: Vaccine Design
17:00 - 17:15 Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
Bert Jacobs, Arizona State University, USA
Presentation

17:15 - 17:30 Replicating measles-SHIV vaccine induces long term preservation of central memory CD4 cells in the gut of vaccinated macaques challenged with SHIV
Frederic Tangy, Institut Pasteur, CNRS, France
Presentation

17:30 - 17:45 Design and Development of DNA vaccines for the Co-expression of micro-RNA and HIV-1 Env
Adam Wheatley, University of Melbourne, Australia
Presentation

17:45 - 18:00 HIV-1 gp41 Envelope MPER Mutation Altered Epitope Conformation in Lipid and Increased Sensitivity to 2F5 and 4E10 Neutralizing Antibodies
Xiaoying Shen, Duke University, USA

18:00 - 18:15 Insertion of the HIV-1 gp41 Epitopes 2F5 and 4E10 into the Membrane-Proximal Region of the Vesicular Stomatitis Virus Glycoprotein
Ivo Lorenz, International AIDS Vaccine Initiative, USA

18:15 - 18:30 Recombinant modified Vaccinia Virus Ankara expressing HIV-1 genes activates NK subset capable of controlling HIV infection in vitro
Jean-Saville Cummings, Institut Pasteur, France

17:00 - 18:30 Oral Abstract Session 3: Modulation of the Immune Response to Infection

17:00 - 17:15 HIV-1 infection is characterized by early loss of CD161+ Th17 Cells and Gradual Decline in Regulatory T cells
Andrew Prendergast, University of Oxford, UK
Presentation

17:15 - 17:30 Regulatory T cells inhibit CD8 T cell proliferation in HIV-1 infection through CD39/Adenosine pathway
Yves Levy, AP-HP, Groupe Henri-Mondor Albert-Chenevier; Universite Paris 12, France

17:30 - 17:45 Increased Regulatory T cell Frequency and HIV-1 Specific Suppression After Therapeutic Vaccination of HIV-Infected Patients on Antiretroviral Therapy
Bernard Macatangay, University of Pittsburgh, USA
Presentation

17:45 - 18:00 Impairment of HIV-1-specific CD8+ T cell function by soluble epithelial adhesion molecules
Hendrik Streeck, Ragon Institute of MGH, MIT and Harvard, USA

18:00 - 18:15 HIV escape from natural killer cytotoxicity: Nef inhibits NKp44L expression on HIV-infected CD4+ T cells.
Vincent Vieillard, INSERM UMR945, France
Presentation

18:15 - 18:30 Unique stimulatory properties of myeloid dendrict cells in individuals with "elite" HIV-1 control
Mathias Lichterfeld, Massachusetts General Hospital, USA


 

Wednesday, 21 October 2009

09:00 - 10:30 Plenary Session 2: In Vivo Response to Pathogens and Vaccines

09:00 - 09:30 In Vivo Dynamics of the Immune Response as Revealed by Multiphoton Imaging
Ron Germain, NIAID NIH, USA

09:30 - 10:00 Efficacy of CMV/SIV Vectors
Louis Picker, Vaccine and Gene Therapy Insitute, OHSU, USA

10:00 - 10:30 TB Vaccine Development
Jerald Sadoff, AERAS Global TB Vaccine Foundation, USA
Presentation
11:00 - 12:30 Oral Abstract Session 4: Update on Clinical Trials

11:00 - 11:15 Safety and Immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: Results of ANRS VAC18, a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Dominique Salmon-Céron, Hôpital Cochin, Université Paris Descartes, France
Presentation

11:15 - 11:30 Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/ modified Vaccinia virus Ankara (MVA) heterologous boost vaccines
Charlotta Nilsson, Swedish Institute for Infectious Disease Control, Karolinska Institute, Sweden
Presentation

11:30 - 11:45 Characterization of cell-mediated immune responses generated by recombinant Modified Vaccinia Ankara (rMVA)-HIV-1 in a Phase I Vaccine Trial
Jeffrey Currie, Military HIV Research Program, USA
Presentation

11:45 - 12:00 Perceived parental willingness for their adolescents to participate in future HIV prevention trials: A survey conducted amongst adolescents in Soweto
Kennedy Otwombe, Perinatal HIV Research Unit, South Africa
Presentation

12:00 - 12:15 Safety and Viral Load changes in HIV-1 Infected Subjects Treated with Autologous Dendritic Immune Therapy following ART discontinuation (CTN#239)
Jean-Pierre Routy, McGill University and INSERM Unit 743, Canada
Presentation

12:15 - 12:30 Post-infection cellular immune responses in recipients following ALVAC-HIV + AISDVax B/E prime-boost vaccination in the Thai phase III trial
Jerome Kim, U.S. Military HIV Research Program (MHRP), USA
Presentation

11:00 - 12:30 Oral Abstract Session 5: New Vaccinal Approaches

11:00 - 11:15 In Vivo Electroporation Enhances the Immunogenicity of ADVAX, a DNA-based HIV-1 Vaccine Candidate, in Healthy Volunteers
Sandhya Vasan, Aaron Diamond AIDS Research Center, Rockefeller University, USA
Presentation

11:15 - 11:30 Analysis of DNA compared to Ad5 vaccination, as single and mixed modalities, demonstrates robust induction of cellular immune responses in macaques
Lauren Hirao, University of Pennsylvania, USA

11:30 - 11:45 Efficacy study of a T-cell-based DNA vaccine delivered by intradermal electrotransfer in macaques
Frédéric Martinon, CEA / Division of Immuno-Virology, France

11:45 - 12:00 Gp96-Ig-SIV vaccines induce predominant immune responses at mucosal sites
Natasa Strbo, University of Miami Miller School of Medicine, USA
Presentation

12:00 - 12:15 Impact of in vivo CD4 binding during HIV-1 Env trimer immunizations of rhesus macaques
Iyadh Douagi, Karolinska Institutet, Sweden
Presentation

12:15 - 12:30 First-in-human phase 1 saftey and immunogenicity of an Adenovirus Serotype 26 HIV-1 vaccine vector
Dan Barouch, Beth Israel Deaconess Medical Center, USA
Presentation

11:00 - 12:30 Oral Abstract Session 6: Dynamics of HIV Infection and the Immune Response

11:00 - 11:15 Multiplicity of infection by HIV-1 in injection drug users, men who have sex with men and heterosexuals
Katharine Bar, University of Alabama at Birmingham, USA
Presentation

11:15 - 11:30 Monospecific Expansion of SIVmac251 During Acute Infection Masks Multiple Transmitted Virus Variants Revealed During the Chronic Phase
Barbara Felber, HRPS, VB, NCI-Frederick, USA

11:30 - 11:45 Dynamics of CTL Epitope Escape and Reversion in an African Subtype C cohort
Malinda Schaefer, Emory University, USA
Presentation

11:45 - 12:00 The Role Of Early T-Cell Responses In Subjects With Acute HIV-1 Infection
Michael Liu, University of Oxford, UK
Presentation

12:00 - 12:15 Adaptation of HIV-1 to the Human Immune System at the Population Level is Driven by Protective HLA-B Alleles
Ingrid Schellens, University Medical Center Utrecht,Netherlands
Presentation

12:15 - 12:30 Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial
James Mullins, University of Washington, USA

12:30 - 14:00 Lunch + Poster Session 02

14:00 - 16:00 Symposium 3: Immunological Memory and Protection

14:00 - 14:25 System Biology to Study Immunological Memory during HIV Infection
Elias Haddad, McGill University, Canada

14:25 - 14:50 Correlates of protection to HIV
Alexandre Harari, Centre Hospitalier Universitaire Vaudois, Switzerland
Presentation

14:50 - 15:15 T Cell Clonotypic Correlates of Virus Control
Daniel Douek, Vaccine Research Center, NIH, USA
Presentation

15:15 - 15:30 Transitional and Central Memory CD4 T Cells are highly infected in Long Term Non Progressors and Elite Controllers
Benjamin Descours, Université Paris VI UPMC, INSERM UMRs945, France

15:30 - 15:45 A Less Differentiated Memory Phenotype of Gag-Specific CD4+ T-cells during Primary HIV Infection Associates with Viral Control at 12 Months
Pholo Maenetje, National Institutes for Communicable Diseases, South Africa
Presentation

15:45 - 16:00 Rapid perforin upregulation by CD8 T cells in elite controllers as a correlate of immune-mediated control of HIV replication
Adam Hersperger, University of Pennsylvania, USA
Presentation

14:00 - 16:00 Symposium 4: Antigen Presentation and T Cell Epitopes

14:00 - 14:25 Semen clusterin binds DC-SIGN and inhibits HIV-1 capture and transmission by dendritic cells
Sebastian Amigorena, Institut Curie, Paris, France
Presentation

14:25 - 14:50 Immune recognition of HIV-1 during acute infection
Marcus Altfeld, Ragon Institute of MGH, MIT and Harvard, USA

14:50 - 15:15 Transcriptional control of crosspresentation programs in dendritic cells
Kenneth Murphy, Washington University School of Medicine, USA

15:15 - 15:30 HIV-specific responses induced by anti-CD40 targeting antibodies
Nicolas Loof, INSERM U899-BIIR/INSERM/ANRS Center for Human Vaccines, USA

15:30 - 15:45 The intracellular production of HIV antigenic peptides is guided by predictable motifs and can be altered: implications for immunogen design
Sylvie Le Gall, Harvard Medical School and Mass General Hospital, USA

15:45 - 16:00 Polyvalent Gag-specific CD8 T-cells with enhanced functional properties are enriched in HIV-1 clade C infected individuals with lower viral loads
Boris Julg, Ragon Institute of MGH, MIT and Harvard, USA
Presentation

16:00 - 17:00 Coffee Break + Poster Viewing
17:00 - 18:40 Symposium 5: Protection Against Mucosal Transmission and Viral Dissemination

17:00 - 17:25 Characterization of viral variants that initiate systemic infection after mucosal transmission
Eric Hunter, Emory Vaccine Center, USA
Presentation

17:25 - 17:50 Target Cell Availability and Prevention of Mucosal Transmission
Ashley Haase, University of Minnesota Medical School, USA

17:50 - 18:15 Do Mucosal T-cell Responses Contribute Significantly to HIV Control?
Barbara Shacklett, UC Davis, USA

18:15 - 18:40 Treatment as Prevention
Bernard Hirschel, University Hospital Geneva, Switzerland
Presentation

17:00 - 18:40 Symposium 6: Refining Immunogen Design

17:00 - 17:25 Structural basis of broad neutralization of HIV-1
Ian Wilson, The Scripps Research Institute, USA

17:25 - 17:50 Primary Immunization Influences the Magnitude, Quality and Breadth of Gag Specific T Cell Responses Following an rAd-5 Boost
Robert Seder, Vaccine Research Center, NIH, USA

17:50 - 18:15 New Applications for Mosaic Antigen Designs
Bette Korber, Los Alamos National Laboratory, USA

18:15 - 18:40 HIV-1 Mosaic Antigens Expand Cellular Immune Breadth and Depth in Rhesus Monkeys
Dan Barouch, Beth Israel Deaconess Medical Centre, Harvard Medical School, USA
Presentation


 

Thursday, 22 October 2009

(Back to Top)
09:00 - 10:30 Plenary Session 3: B Cell Biology

09:00 - 09:30 Development of anti-HIV antibodies in humans with high titers of broadly neutralizing antibodies
Michel Nussenzweig, Howard Hughes Medical Institute, The Rockefeller University, USA

09:30 - 10:00 From Antibody to Vaccine - a Tale of Structural Biology and Epitope Scaffolds
Peter Kwong, Vaccine Research Center, NIH, USA
Presentation

10:00 - 10:30 Induction and Function of the Mucosal Immune System
Per Brandtzaeg, University of Oslo, Norway
Presentation

11:00 - 11:45 Oral Abstract Session 7: T Cell Responses to Vaccine

11:00 - 11:15 HIV-Specific CD8+ T-Cells of Vaccinees Exhibit Proliferative and Cytotoxic Capacities Comparable to Those of Progressors
Julia Rood, National Institute of Health, USA
Presentation

11:15 - 11:30 Adenovirus vectors induce expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 infection.
Adel Benlahrech, Imperial College, UK
Presentation

11:30 - 11:45 Influence of Preexisting Vaccinia Immunity on a DNA/MVA SIV Vaccine, Decreased Cellular Immunity but Enhanced Control of a Pathogenic SIV Challenge
Rama Amara, Yerkes National Primate Center of Emory University, USA

11:45 - 12:45 Closing Session

11:45 - 12:10 HIV Vaccinology: What Does the Future Hold?
Anthony Fauci, NIAID, NIH, USA
Presentation

12:10 - 12:35 Are we targeting the right HIV determinants?
Françoise Barré-Sinoussi, Institut Pasteur, France
Presentation

12:35 - 12:45 Closing Remarks and Handover

12:35 - 12:40 Yves Levy, ANRS, France
12:40 - 12:45 Eric Hunter, Emory Vaccine Center, USA
Presentation